Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant.

PHASE1Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

September 30, 2026

Study Completion Date

September 30, 2026

Conditions

Multiple MyelomaAmyloidosis

Interventions

DEVICE

Melphalan

DRUG

Pegfilgrastim

PROCEDURE

Autologous Hematopoietic Progenitor Cell Transplant

Trial Locations (1)

Memorial Sloan Kettering Cancer Center, New York

All Listed Sponsors

collaborator

Spectrum Pharmaceuticals, Inc

INDUSTRY

lead

Memorial Sloan Kettering Cancer Center

OTHER